Jan 24 | News
Takeda on Monday announced that the FDA approved a label update for Velcade (bortezomib) to include subcutaneous administration of the drug in all approved indications.
|
Jan 18 | News
Takeda Pharmaceutical Company Limited announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth.
|
Dec 21 2011 | News
Takeda Pharmaceutical Company Limited and Intellikine, Inc. today announced that Takeda America Holdings, Inc., a wholly-owned subsidiary of Takeda, and Intellikine, a privately-held company focused on the discovery and development of innovative, small molecule drugs, have entered into an agreement for Takeda America Holdings to acquire Intellikine by cash. Takeda expects that the transaction will be finalized in January 2012. Under the agreement, Takeda America Holdings will acquire Intellikine for $190 million upfront and up to $120 million in additional potential clinical development milestone payments.
|
Nov 4 2011 | News
Takeda announced Friday a reduction of its full-year net income forecast by 32 percent due to costs related to the 9.6-billion euro ($13.3 billion) takeover of Nycomed and the stronger Japanese currency.
|
Sep 30 2011 | News
Takeda Pharmaceutical Company Limited announced it has completed its acquisition of Nycomed A/S for 9.6 billion Euro on a cash-free, debt-free basis and made Nycomed a wholly owned subsidiary
|
Aug 10 2011 | News
Affymax Inc. received a $10 million milestone
payment from partner Takeda Pharmaceutical Co., the company said Wednesday,
after federal regulators accepted an application for the potential anemia
treatment peginesatide.
|
Jul 26 2011 | News
Takeda Pharmaceutical Company Limited announced today that
Takeda Global Research & Development Center, Inc., resubmitted two New Drug
Applications (NDA) to the FDA for alogliptin and the fixed-dose combination
therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in
a single tablet.
|
Jul 22 2011 | News
The European Medicines Agency recommended Thursday that a warning be
added to the label of Takeda's Actos (pioglitazone) regarding a "small
increased risk of bladder cancer."
|
May 16 2011 | News
Breckenridge Pharmaceutical has announced that it and Synthon Pharmaceuticals have reached an agreement with
Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America
resolving patent litigation related to Pioglitazone Hydrochloride 15 mg, 30 mg
and 45 mg tablets, a generic equivalent version of Actos.
|
May 10 2011 | News
Paladin Labs Inc. and Takeda Pharmaceutical Company Limited
announced today that they have entered into a licensing and distribution
agreement under which Paladin has granted Takeda an exclusive right to develop
and commercialize fomepizole (marketed and distributed by Paladin under the
trademark Antizol in Canada and the United States) for the treatment of
ethylene glycol and methanol poisonings in Japan.
|